Eupraxia Pharmaceuticals (EPRX) Receives a Buy from Cantor Fitzgerald
I'm PortAI, I can summarize articles.
Eupraxia Pharmaceuticals (EPRX) has received a Buy rating from Cantor Fitzgerald, with a price target of $19.00 set by analyst Kristen Kluska. Kluska, a 5-star analyst, has an average return of 24.4% and a success rate of 46.75%. The consensus for Eupraxia Pharmaceuticals is a Strong Buy, with a price target consensus of $15.22.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments